Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment

Figure 1

3-year relapse-free survival between BioRT and SD-CCRT group. 3-year RFS is 65.8% in SD-CCRT group versus 65.5% in BioRT group (𝑃=0.647).